For CROs & Sponsors
On average, it takes 500 feasibility requests to get just 50 replies. What's worse? For every 100 sites activated, only 20 produce the results.
If theres' so much data, why can't you just select the best sites for your study without actually having to ask hundreds of sites first, and getting delayed, patchy data? When there's a match, shouldn't it be as easy as an Uber transaction between driver and passenger?
Sound like science fiction? Not anymore.
For Research Sites
Your life blood is new trials but you are drowning in paperwork. Feasibility requests require printing, completing, scanning and returing - with the SAME data - over and over again. If there's any tech at all, you are required to log into multiple portals. Nothing is tracked.
Why can't sponsors and CROs just know what you can do and bring you the trials that work for you and your patients? Now they can.
Join the Ryght Research Network. It's free.
Apps for AI Builders
Ryght has developed an enterprise class, SOC2 compliant, scalable platform and tools that underly a new age of clinical research applications.
Get a 10X lift across the realms of:
- Synthetic, digital twinning
- Protocol navigation
- Study selection
- Medical writing
- Rapid site activation
"By streamlining study selection, feasibility, and patient referrals, the Ryght Research Network will allow us to focus more on advancing patient care and less on administrative burden while running the trials that are most likely to succeed."
David Friedland
M.D, Ph.D., Associate Dean of Clinical Research
Keck School of Medicine of the University of Southern California
“Ryght AI's unique and powerful platform streamlines clinical trials from site selection to activation and enrollment, ultimately speeding up time to market for our biopharma clients.”
Derek Grimes
Executive Vice President and Global Head of Clinical Research
QPS
"We are thrilled to collaborate with Ryght and utilize their GenAI platform to advance our clinical trial processes. Through the application of AI, we aim to further support our biotech clients to develop transformative therapeutics in areas of unmet need.”
Yvonne Lungershausen
CEO
Avance Clinical
"Ryght's cutting-edge technology aligns perfectly with our commitment to innovation that enables our customers to rapidly identify clinically qualified patients, leading to faster enrollment in clinical trials.
By harnessing the power of AI, we can continue to unlock new insights and accelerate access to clinical research."
Dave Levin
CEO
BEKhealth
"At the University of Adelaide, we are committed to advancing world-class research that addresses many of the challenges faced by society. By working together, we can leverage our collective expertise to develop innovative, responsible and tested solutions for better public health and other critical issues and bring Australia’s AI capabilities up to world-class standards where they belong.”
Professor Mark Hutchinson BSc, PhD
Interim Director of the Institute for Photonics and Advanced Sensing (IPAS)
Adelaide University
